Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the combination of vicadrostat BI 690517 and empagliflozin for adults aged 18 and older who have heart failure symptoms and a left ventricular ejection fraction LVEF of 40% or more. The study aims to find out whether taking vicadrostat with empagliflozin helps people with heart failure. This is a phase III randomized, double-blind, parallel-group trial sponsored by Boehringer Ingelheim. Participants are randomly assigned to one of two groups one group takes vicadrostat combined with empagliflozin tablets once daily, and the other group takes a placebo combined with empagliflozin tablets once daily. The study has no fixed duration participants can stay in the study as long as they benefit from treatment and can tolerate it. During the study, participants visit their doctors regularly for health checks and monitoring. Throughout the study, participants undergo regular health assessments including monitoring for any unwanted effects. Study staff may also contact participants by phone and ask them to answer questions about their well-being. The main outcome being measured is the time to the first event of cardiovascular death, hospitalization for heart failure, or urgent heart failure visit over up to 42 months. Other outcomes include symptom scores, blood pressure changes, and kidney function. The study runs until enough data is collected to evaluate the treatments effects.
Actively Recruiting
Researchers are evaluating a new chemotherapy drug called JSKN003 in people with recurrent or metastatic breast cancer that is HER2-low and cannot be removed by surgery. This phase III clinical trial compares JSKN003 to chemotherapy drugs chosen by doctors in patients who have already tried and not responded to one or two previous chemotherapy treatments. The study aims to assess the safety and effectiveness of JSKN003 in this group of patients. Participants are randomly assigned to one of two groups one group receives JSKN003 alone given by intravenous infusion, while the other group receives one chemotherapy drug selected by their doctor from options like capecitabine, gemcitabine, vinorelbine, docetaxel, albumin-bound paclitaxel, or eribulin. The choice of the chemotherapy drug for the control group is made before randomization. Treatment schedules follow the study protocol at multiple centers. During the study, participants will have regular assessments including scans to measure tumor progression and other tests to evaluate response and overall survival, monitored for up to about three years after enrollment. Researchers will track progression-free survival as the main outcome, along with overall survival, response rate, and duration of response. Safety and side effects will also be closely monitored throughout the study.
Actively Recruiting
Researchers are evaluating the real-world clinical outcomes of adult patients in China who have had surgery for stage II to IIIB anaplastic lymphoma kinase ALK-positive non-small-cell lung cancer NSCLC and were treated with Alectinib as adjuvant therapy. This multicenter, prospective cohort study aims to better understand the disease-free survival and other clinical characteristics of these patients over time. Participants in this observational study have already received Alectinib following their surgery as part of routine clinical care. The study does not provide any additional treatments but follows patients who have taken Alectinib monotherapy without prior systemic therapy, including other ALK-targeted therapies or chemotherapy. Patients will be observed during their routine clinical visits for about 2.5 years. During the study, researchers will collect information on disease recurrence or death, treatment duration, participant demographics, clinical characteristics including performance status and surgery history, and quality of life using questionnaires every three months. Adverse events related to Alectinib will also be monitored from baseline until 28 days after the last dose or withdrawal. The total follow-up period for each participant is approximately 2.5 years.
Actively Recruiting
Researchers are studying Rina-S, a targeted antibody-drug conjugate aimed at treating participants with solid tumors that are either metastatic or cannot be removed by surgery. This Phase 12 trial evaluates Rina-Ss safety, side effects, how the body processes the drug, and its potential anti-tumor effects across various cancers including ovarian, endometrial, breast, lung, and mesothelioma. Participants receive Rina-S either alone or in combination with other cancer drugs like carboplatin, bevacizumab, pembrolizumab, or CYP3A4 inhibitors such as erythromycin or itraconazole. The study includes multiple parts, each focusing on different tumor types or combinations of therapies. Treatment continues until disease progression, unacceptable side effects, withdrawal of consent, or other specified reasons. During the study, participants undergo regular evaluations including monitoring for side effects, tumor response assessments using imaging criteria, and blood tests to measure drug levels and antibodies. Safety and effectiveness data are collected for up to about one year, with some outcomes followed for up to two years. Participants remain under medical supervision throughout the trial duration, which runs until March 2029.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of combining Zorifertinib with Osimertinib for people who have advanced Non-Small Cell Lung Cancer NSCLC that has spread to the membranes around the brain and spinal cord, known as leptomeningeal metastases. This study focuses on patients who have already been treated with Osimertinib but experienced progression in the meningeal area. The trial is a Phase 1 study designed to find the recommended dose and further assess safety and treatment response. All participants will receive both Zorifertinib and Osimertinib. Zorifertinib is given orally twice daily at increasing doses starting at 100 mg, while Osimertinib is taken once daily at a fixed dose of 80 mg. The study has two parts Part A involves dose escalation to identify the best dose for further use, and Part B expands the number of participants receiving the recommended dose to evaluate safety, effectiveness, and how the body processes the drugs. Treatment continues until the cancer worsens, side effects become unacceptable, or other stopping criteria are met. Participants will be monitored through regular assessments including neurological exams, brain and spinal imaging, and cerebrospinal fluid tests. Researchers will measure dose-limiting toxicities during the first 21 days, track adverse events and serious side effects for up to 12 months, and evaluate tumor responses using standardized criteria. Outcomes such as progression-free survival, response rates in the brain and overall tumors, and changes in neurological function will be closely followed. The study may last until September 2028, with safety and effectiveness data collected throughout treatment.